Genferon light nasal drops, 10ml

Genferon light nasal drops, 10ml

Treatment of influenza and other acute respiratory viral infections in children aged 29 days to 14 years.

At the first signs of the disease, Genferon Light is instilled into the nose for 5 days.

Children from 29 days to 11 months 29 days - 1 drop in each nasal passage 5 times a day (single dose of 1,000 IU, daily dose of 5,000 IU).

Children from 1 to 3 years old - 2 drops in each nasal passage 3-4 times a day (single dose 2,000 IU, daily 6,000-8,000 IU).

Children from 3 to 14 years old - 2 drops in each nasal passage 4-5 times a day (a single dose of 2,000 IU, a daily dose of 8,000-10,000 IU).

1 ml

interferon alpha-2b human recombinant * 10,000 IU

taurine 0.8 mg

Excipients: disodium edetate dihydrate - 0.02 mg, glycerol - 7 mg, dextran 35-45 thousand - 2.4 mg, polysorbate 80 - 1 mg, sodium chloride - 0.8 mg, potassium chloride - 0.02 mg, sodium hydrogen phosphate - 0.115 mg, sodium dihydrogen phosphate - 0.02 mg, water d / i - up to 1 ml.

• Hypersensitivity to interferon alfa-2b or other components of the drug;

• newborns from 0 to 28 days (due to lack of clinical data).

pharmachologic effect

The drug Genferon Light, nasal drops, has antiviral, immunomodulatory, anti-inflammatory, antiproliferative, antibacterial effect, has local regenerating, membrane stabilizing and antioxidant properties. Interferon alpha blocks the multiplication of viruses at the stage of synthesis of specific proteins and prevents infection of uninfected cells of the nasal mucosa, which is the site of invasion of pathogens and the primary focus of inflammation in respiratory infections. The immunomodulatory effect is manifested by an increase in the cell-mediated responses of the immune system, which increases the effectiveness of the immune response against foreign agents. This is achieved by activating CD8 + T-killers, NK-cells (natural killers), enhancing the differentiation of B-lymphocytes and their production of antibodies,activation of the monocyte-macrophage system and phagocytosis, as well as an increase in the expression of molecules of the main histocompatibility complex type 1, which increases the likelihood of recognition of infected cells by cells of the immune system. The activation of leukocytes contained in all layers of the mucous membrane under the influence of interferon ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by the reactions of the immune system, enhanced by iodine by the influence of interferon. Taurine, which is part of the drug, normalizes metabolic processes in tissues, promotes regeneration and faster recovery of the nasal mucosa damaged by the pathological process.

Pharmacokinetics

When used intranasally, Genferon Light, nasal drops, creates a high concentration of interferon in the focus of infection and has a pronounced local antiviral and immunostimulating effect. Systemic absorption of the drug is insignificant, with intranasal administration of human recombinant alpha-2b interferon in a small amount is determined in lung tissue and blood. In the body, biotransformation occurs mainly in the kidneys with a T1 / 2 of 5.1 hours. A small amount of the drug entering the systemic circulation has a systemic immunomodulatory effect.

Side effect

Local allergic reactions (burning sensation, itching) are possible. These phenomena are reversible and disappear on their own within 72 hours after stopping the use of the drug. Continuation of treatment is possible only after consulting a doctor.

Application during pregnancy and lactation

Not used because the drug is indicated for use in children aged 29 days to 14 years.

Application in children

Contraindicated in newborns up to 28 days of age.

special instructions

After instillation, it is recommended to massage the wings of the nose with your fingers for several minutes to evenly distribute the drug in the nasal cavity.

Influence on the ability to drive vehicles and use mechanisms

The effect of Genferon Light on the performance of potentially hazardous activities that require special attention and quick reactions (driving vehicles, machinery, etc.) has not been studied.

Overdose

Overdose cases of Genferon Light have not been registered to date.

Drug interactions

The simultaneous use of intranasal vasoconstrictor drugs is not recommended, since this causes additional dryness of the nasal mucosa.